株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

子宮頸癌の診断薬と治療薬市場 - 成長、傾向、予測(2019年~2024年)

Cervical Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 353906
出版日 ページ情報 英文 116 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.21円で換算しております。
Back to Top
子宮頸癌の診断薬と治療薬市場 - 成長、傾向、予測(2019年~2024年) Cervical Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年02月01日 ページ情報: 英文 116 Pages
概要

世界の子宮頸癌診断および治療薬市場は、政府による予防への取り組みや、罹患率の上昇、早期診断に対する関心の高まり、主要企業の子宮頸癌への力強い研究開発などによって、成長が促進されています。

当レポートでは、子宮頸癌診断および治療薬の世界市場を調査し、市場の概要、診断検査・治療薬・エンドユーザー別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場の成長要因
    • 政府による子宮頸癌予防の取り組み
    • 子宮頸癌の罹患率の上昇
    • 早期診断の関心の高まり
    • 子宮頸癌の診断および治療薬の研究開発
  • 市場の阻害要因
    • 定期健診の導入に際する経済的課題
    • 癌治療のコストの高さ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第5章 市場セグメンテーション

  • 診断検査別
    • パップテスト(子宮頸部細胞診)
    • ヒトパピローマウイルス(HPV)検査
    • コルポスコピー
    • 生検・子宮頸管内掻爬
    • その他
  • 治療薬別
    • アバスチン(ベバシズマブ)
    • ブレオキサン(ブレオマイシン)
    • ヒカムチン(トポテカン塩酸塩)
    • ゲムシタビン - シスプラチン
    • ワクチン
    • その他
  • エンドユーザー別
    • 病院
    • 専門クリニック
    • 癌/放射線療法センター
    • 診断センター
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Abbott Laboratories
    • Bristol-Meyrs Squibb Company
    • GlaxoSmithKline PLC
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Qiagen NV
    • Advaxis Inc.
    • Becton, Dickinson and Company
    • F. Hoffmann-La Roche Ltd

第7章 市場機会と将来動向

目次
Product Code: 56560

Market Overview

The factors propelling the growth of the cervical cancer diagnostics and therapeutics market are favorable government initiatives toward cervical cancer prevention, the growing prevalence of cervical cancer, an increase of awareness regarding early diagnosis, and strong R&D from key players for cervical cancer diagnosis and drugs.

The market studied has been witnessing considerable growth, which is attributed to the increasing prevalence of cervical cancer among women, worldwide. According to the World Health Organization (WHO), more than 270,000 women die every year due to cervical cancer. The cervical cancer mortality rate is higher in developing countries, due to improper detection at early stages of the disease. With the rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer, the market is expected to grow.

Increasing awareness among the general population regarding the care, prevention, and treatment of cervical cancer, the rise in certain behaviors such as sex with multiple-partners and smoking, certain genetic factors, and weak immune system are all linked to the growth of the cervical cancer diagnostics and therapeutics market.

Awareness programs have helped in the growth of the market. For instance, Medicaid, the popular government insurance program, covers the screening for cervical cancers. Medicare, another widely used insurance, covers Pap test, pelvic exam, and clinical breast exam for cervical cancer screening, every two years. These programs were found to be responsible for the growth of the overall market.

Scope of the Report

Cervical cancer refers to a malignancy of cervical cells. More than 90% of cervical malignancies occur due to HPV infection (human papillomavirus), which can be diagnosed through smear screening. The most common types of cervical cell cancer are squamous cell malignancy and adenocarcinoma. Cervical cancer diagnostic tests are being widely used for the detection of precancerous or cancerous lesions in the cervix of females.

Key Market Trends

Pap Smear Test, the Largest Segment Under Diagnostic Test, is Expected to Grow During the Forecast Period

Pap smear test, the most effective tool for the diagnosis of HPV, was found to be the most revenue-generating segment. Factors, such as the increasing prevalence of HPV infection in women and the deficiency of the HPV vaccine, which does not cover all types of HPV infections, are promoting the growth of the market.

North America, which Holds the Largest Share in the Market, is Expected to Follow the Same Trend, Over the Forecast Period

North America is the largest market for cervical cancer diagnostics and therapeutics. The large market share is attributed to the high awareness about disease prevention among women in the region, as well as to the many initiatives launched to prevent cervical cancer, which has increased the reach of insurance coverage for cervical screening tests, especially for low-income women.

Asia-Pacific, the fastest growing market for cervical cancer diagnostic tests, attributes its growth to the increasing prevalence of cervical cancer in developing countries, including China, India, Malaysia, Japan, South Korea, and Australia.

Competitive Landscape

Intense competition was observed in the market for cervical cancer diagnostics and therapeutics, due to the presence of a large number of cervical cancer patients. Companies are currently focusing on developing advanced techniques for diagnosis, such as liquid-based cytology.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Favorable Government Initiatives Toward Cervical Cancer Prevention
    • 4.2.2 Growing Prevalence of Cervical Cancer
    • 4.2.3 Increasing Awareness Regarding Early Diagnosis
    • 4.2.4 Strong R&D from Key Players for Cervical Cancer Diagnosis and Drugs
  • 4.3 Market Restraints
    • 4.3.1 Economic Constraints in Many Countries to Adopt Regular Testing Procedures
    • 4.3.2 High Cost of Cancer Therapies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Diagnostic Test
    • 5.1.1 Pap Smear Test
    • 5.1.2 HPV Test
    • 5.1.3 Colposcopy
    • 5.1.4 Biopsy and Endocervical Curettage
    • 5.1.5 Other Diagnostic Tests
  • 5.2 By Therapeutic
    • 5.2.1 Avastin (Bevacizumab)
    • 5.2.2 Blenoxane (Bleomycin)
    • 5.2.3 Hycamtin (Topotecan Hydrochloride)
    • 5.2.4 Gemcitabine-Cisplatin
    • 5.2.5 Vaccines
      • 5.2.5.1 Gardasil
      • 5.2.5.2 Cevarix
    • 5.2.6 Other Therapeutics
  • 5.3 By End User
    • 5.3.1 Hospitals
    • 5.3.2 Specilty Clinics
    • 5.3.3 Cancer and Radiation Therapy Centers
    • 5.3.4 Diagnostic Centers
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Bristol-Meyrs Squibb Company
    • 6.1.3 GlaxoSmithKline PLC
    • 6.1.4 Merck & Co. Inc.
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Qiagen NV
    • 6.1.7 Advaxis Inc.
    • 6.1.8 Becton, Dickinson and Company
    • 6.1.9 F. Hoffmann-La Roche Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top